This bridge program will now allow Medicare beneficiaries access to GLP-1 medications for weight loss through a monthly subscription model, which raises important questions about who pays, how much it will cost, and whether the program can be sustained long term, Kevin Thompson, the CEO of 9i Capital Group and the host of the 9innings podcast, told Newsweek
Most of the studies in fact, all the studies that we've seen now where we use patient-reported outcomes, meaning how's your physical functioning, in the trials they all go up across the board
Exendin-4 is a 39 amino acid peptide with 53% identity to GLP-1 (34) and is fully active at GLP-1 receptors and not degraded by DPP-4
No insurance, can't afford brand: Older oral options (phentermine $20-$60/mo, Contrave $99-$199/mo with savings card)
Keep your prescription documentation handy in case security has questions about syringes and vials
The triple agonist mechanism targets complementary metabolic pathways simultaneously GLP-1 for appetite suppression and insulin secretion, GIP for enhanced incretin response, and glucagon for energy expenditure with the goal of achieving weight loss exceeding that seen with dual agonists such as tirzepatide